Nawaz Khan is the Head of Research at BioVersys, bringing over 20 years of drug discovery experience across oncology, pain, and infectious diseases. A co-founder of Discuva with a PhD from the University of Cambridge, he has a proven track record of building and managing successful multi-disciplinary research teams.
As a founding member of Discuva, he was a key part of the team that secured a worldwide collaboration and license agreement with Roche for new antibiotics.
Read the full overview →
Experience
27 Years
Current Role
Head of Research
Job Level
Mid-senior
Location
Greater Cambridge Area, United Kingdom
Personality Overview
How Nawaz shows up
Curious
Value Driven
Assertive
They are generally strong communicators and are not easy to convince. They can sound friendly and charming but can quickly change gears to become inquisitive and probing. They ask a lot of questions and rely heavily on information and collaterals.
Priorities
Topics Nawaz cares about
Combating AMR
His work focuses on discovering new antibiotics for multi-drug resistant bacteria, and he recently engaged with the Helmholtz Institute on innovative programs to tackle Antimicrobial Resistance (AMR).
Novel Antibiotics
He leads research into new treatments for life-threatening infections, including multi-drug resistant Gram-negative bacteria and non-tuberculous mycobacteria (NTM).
+4 more topicsLogin to view topics
Career
Work history
10-2023
Head of Research
BioVersys AG
12-2021 - 5-2023
Vice President Research (Oncology)
Summit Therapeutics
1-2018 - 5-2023
Vice President Research (Infectious Disease)
Summit Therapeutics
3-2010 - 12-2017
Research Director, Co-Founder
Discuva
2-2007 - 6-2009
Head of Chemistry
Lectus Therapeutics
In the press
Media appearances
Nawaz Khan, BioVersys AG: Profile and Biography. Featured in Bloomberg
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
More profiles
Discover additional public profiles from our index.